Edition:
United Kingdom

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

89.41CHF
14 Jun 2019
Change (% chg)

CHF0.41 (+0.46%)
Prev Close
CHF89.00
Open
CHF88.70
Day's High
CHF89.83
Day's Low
CHF88.49
Volume
3,282,987
Avg. Vol
5,045,587
52-wk High
CHF96.20
52-wk Low
CHF71.84

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 1.06
Market Cap(Mil.): CHF227,178.00
Shares Outstanding(Mil.): 2,527.38
Dividend: 2.85
Yield (%): 3.13

Financials

  NOVN.S Industry Sector
P/E (TTM): 16.93 32.88 37.45
EPS (TTM): 5.31 -- --
ROI: 13.18 12.53 12.16
ROE: 21.05 13.82 16.93

BRIEF-Novartis Says Sandoz’ Hyrimoz Phase III Study Meets Endpoints

* DATA FROM PHASE III ADMYRA TRIAL DEMONSTRATING THAT EFFICACY AND SAFETY OF SANDOZ BIOSIMILAR HYRIMOZ® (ADALIMUMAB)* MATCHES THAT OF REFERENCE MEDICINE ADALIMUMAB** WITH NO CLINICALLY MEANINGFUL DIFFERENCES

14 Jun 2019

BRIEF-Novartis Says Cosentyx Shows Efficacy In Key Manifestations Of Psoriatic Arthritis

* NOVARTIS COSENTYX® FIRST TO SHOW EFFICACY IN ALL KEY MANIFESTATIONS OF PSORIATIC ARTHRITIS

12 Jun 2019

NEWSMAKER-France's Sanofi bets on new CEO to drive sluggish drug sales

ZURICH, June 7 In veteran drug salesman Paul Hudson, Sanofi's 100,000-plus employees are getting a new chief executive who relishes a good commercial fight.

07 Jun 2019

Drugmaker Sanofi hires Hudson from Novartis as CEO

PARIS Sanofi has poached Paul Hudson from Novartis to replace Chief Executive Olivier Brandicourt who will retire in September, France's biggest drugmaker said on Friday, helping send its shares almost 5 percent higher.

07 Jun 2019

Drugmaker Sanofi hires Hudson from Novartis as CEO

PARIS Sanofi has poached Paul Hudson from Novartis to replace Chief Executive Olivier Brandicourt who will retire in September, France's biggest drugmaker said on Friday, helping send its shares almost 5 percent higher.

07 Jun 2019

UPDATE 3-Drugmaker Sanofi hires Hudson from Novartis as CEO

* Hudson from Novartis to join Sanofi from Sept. 1 * Current CEO Brandicourt to retire * Shares up almost 5 percent (Adds share price, comment) By Matthias Blamont PARIS, June 7 Sanofi has poached Paul Hudson from Novartis to replace Chief Executive Olivier Brandicourt who will retire in September, France's biggest drugmaker said on Friday, helping send its shares almost 5 percent higher. Hudson, who is British, will take over on Sept. 1,

07 Jun 2019

CORRECTED-UPDATE 2-Drugmaker Sanofi appoints Novartis' Hudson as CEO

PARIS, June 7 Sanofi has appointed Novartis executive Paul Hudson to replace CEO Olivier Brandicourt who will retire in September, France's biggest drugmaker said on Friday.

07 Jun 2019

Swiss drugmaker Novartis names new drug division head

ZURICH Swiss pharmaceuticals giant Novartis named Marie-France Tschudin head of its main drugs business after its previous manager, Paul Hudson, was poised to take the CEO position at French drugmaker Sanofi.

07 Jun 2019

Swiss drugmaker Novartis names new drug division head

ZURICH Swiss pharmaceuticals giant Novartis named Marie-France Tschudin head of its main drugs business after its previous manager, Paul Hudson, was poised to take the CEO position at French drugmaker Sanofi.

07 Jun 2019

Swiss drugmaker Novartis names new drug division head

ZURICH, June 7 Swiss pharmaceuticals giant Novartis named Marie-France Tschudin head of its main drugs business after its previous manager, Paul Hudson, was poised to take the CEO position at French drugmaker Sanofi .

07 Jun 2019

Earnings vs. Estimates